Phase II Study of Myeloablative Preparative Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Patients Undergoing Unrelated Umbilical Cord Blood Transplantation for Hematologic Malignancies.

Trial Profile

Phase II Study of Myeloablative Preparative Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Patients Undergoing Unrelated Umbilical Cord Blood Transplantation for Hematologic Malignancies.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Ciclosporin; Filgrastim; Mycophenolate mofetil
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 07 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 22 Jan 2016 Planned End Date changed from 1 Aug 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top